Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5763 - PD-L1 Expression and T-Cell Inflamed Gene Expression Profile (GEP) in Korean and US Patients (pts) With Advanced Gastric Cancer (GC)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Immunology

Tumour Site

Gastric Cancer

Presenters

Sun Young Rha

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

S.Y. Rha1, G.Y. Ku2, H.S. Kim3, H.C. Chung4, F.G. Amlashi5, D.M. Maru6, C. Fein2, L. Tang7, M.J. Savage8, W. Zhou8, T. Wu8, S.A. Peter9, D.P. Kelsen10, J.A. Ajani5

Author affiliations

  • 1 Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 110-752 - Seoul/KR
  • 2 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 3 Medical Oncology And Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 4 Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 5 Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 6 Pathology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 7 Pathology, Memorial Sloan Kettering Cancer Center, New York/US
  • 8 Medical Oncology, Merck & Co., Inc., Kenilworth/US
  • 9 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 10 Medical Oncology, Merck & Co., Inc., New York/US
More

Resources

Abstract 5763

Background

PD-L1 expression and GEP have been associated with response to anti–PD-1/PD-L1 therapy. We studied PD-L1 expression and GEP in pts receiving standard therapy for GC in South Korea and the US in an observational study.

Methods

Tumor samples were collected from 2003-2017 from the Yonsei Cancer Center (South Korea), MD Anderson Cancer Center (US), and Memorial Sloan Kettering Cancer Center (US). PD-L1 expression was assessed by PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies); PD-L1+ was defined as combined positive score (CPS) ≥1. GEP was analyzed only in Korean pts. GEP score was derived from an 18-gene signature measured using extracted tumor RNA analyzed by NanoString nCounter platform. High/low GEP was based on a cutoff of –0.318. PD-L1 expression was analyzed using chi-squared and multiple logistic regression; survival was estimated using the Kaplan-Meier method, log-rank test, and Cox proportional hazards models.

Results

574 tumor samples (73% biopsy, 27% surgical resection) from pts with GC (median [range] age 61 [21-90] years) were analyzed. Of the 574 pts, 49% (277/567) had stage IV disease; 43% (249/574) had operable disease (half of whom received adjuvant chemotherapy), and 57% (325/574) had inoperable disease (74% received chemotherapy, 18% received chemoradiation). The prevalence of PD-L1+ expression was 67% overall, 69% in Korean pts, 66% in US pts, 68% in biopsy samples, and 67% in surgical resection samples. Greater PD-L1+ expression was seen in older (≥65 years) vs younger pts (P = 0.011) and in pts with inoperable vs operable disease (P < 0.0001). PD-L1 expression was not associated with overall survival (OS) (log-rank test P = 0.25). 85% (243/286) of Korean pts had high GEP. High GEP was associated with tumor grade (P < 0.001) and clinical stage (P < 0.0001). High GEP may be associated with longer OS (adjusted hazard ratio 0.46 [95% CI 0.32-0.66]). GEP was mildly correlated with PD-L1 CPS (Spearman r = 0.24 [P < 0.0001]).

Conclusions

PD-L1 expression was similar in Korean and US pts with GC and in biopsy and surgical resection samples. GEP was associated with OS while PD-L1 expression was not. Further investigation of GEP with anti–PD-1/PD-L1 therapy is warranted.

Clinical trial identification

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Editorial Acknowledgement

Medical writing and/or editorial assistance was provided by Sarita S. Shaevitz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

S.Y. Rha: Advisory board member: Eli Lilly, MSD, Celltrion, Ipsen; Speakers\' bureau: Eli Lilly; Institution research funding: MSD, BMS. G.Y. Ku: Advisory board member: Merck & Co., Inc., Eli Lilly, AstraZeneca; Institution research funding: Merck & Co. Inc., BMS, Arog Pharmaceuticals, AstraZeneca. H.C. Chung: Advisory board member: Taiho, Celltrion, MSD, Eli Lilly, Quintiles, BMS, Merck-Serono; Speakers\' bureau: Merck-Serono, Lilly, Foundation Medicine; Institution research funding: Lilly, GSK, MSD, Merck-Serono, BMS-Ono, Taiho. C. Fein: Employee of Novant Health; Travel expenses, accommodations: Aduro Biotech. M.J. Savage, W. Zhou, S.A. Peter: Employee, Stock owner: Merck & Co., Inc. T. Wu: Employee of Merck & Co., Inc. at the time the analysis was conducted for this abstract. J.A. Ajani: Institution research funding: BMS, Merck & Co., Inc., Taiho, DeltaFly, Gilead. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.